Spelling suggestions: "subject:"cytochrome 0.450 CYP2D6"" "subject:"cytochrome 0,450 CYP2D6""
11 |
Drug-related problems with special emphasis on drug-drug interactionsMannheimer, Buster, January 2009 (has links)
Diss. (sammanfattning) Stockholm : Karolinska institutet, 2009. / Härtill 4 uppsatser.
|
12 |
Characterization of CYP2D protein from human brain cerebellumBhatia, Deepak. January 2004 (has links)
Thesis (M.S.)--West Virginia University, 2004 / Title from document title page. Document formatted into pages; contains ix, 49 p. : ill. (some col.). Includes abstract. Includes bibliographical references (p. 41-48).
|
13 |
Functional evaluation of cytochrome P450 2D6 allelic isoformsZhang, Weiyan, January 1900 (has links)
Thesis (Ph. D.)--West Virginia University, 2005. / Title from document title page. Document formatted into pages; contains viii, 141 p. : ill. (some col.). Includes abstract. Includes bibliographical references.
|
14 |
Pharmacogenetic and environmental determinants of response to HMG-CoA reductase inhibitors. / CUHK electronic theses & dissertations collectionJanuary 2007 (has links)
A total of 146 Chinese patients with various degrees of hyperlipidaemia and high cardiovascular risk, suitable for treatment with rosuvastatin 10 mg daily and in whom it was possible to obtain baseline lipid profiles measured on no lipid lowering drug, were enrolled in to the study. The drug compliance was assessed by personal interview and 9 patients were excluded from the efficacy analysis because they stated their compliance was less than 80%. From the remaining 137 subjects, 62 had a clinical diagnosis of familial hypercholesterolaemia. Data for dietary intake were available in 121 of the 137 subjects. The average reduction in LDL-cholesterol in these subjects was 48.8 +/- 12.8% and as anticipated there was a wide range between individuals. The percentage reductions in LDL-cholesterol were significantly greater in the female than in the male subjects (-51.35 +/-10.89% vs. -46.38 +/-13.96%; p = 0.025), but this was no longer significant after adjustment for body weight. In patients with familial hypercholesterolaemia the absolute reductions in total cholesterol and LDL-cholesterol were significantly greater (p<0.001) than in those without familial hypercholesterolaemia, but the percentage reductions were not significantly different in the two groups. The increases in HDL-cholesterol and the decreases in triglycerides were significantly greater in the subjects with familial hypercholesterolaemia than in those without familial hypercholesterolaemia, both for the absolute changes and for the percentage changes. There were no significant effects on the percentage changes in lipids with rosuvastatin treatment due to age, measurements of body fatness, smoking or alcohol drinking status, or having hypertension or diabetes. / Polymorphisms in the CYP2D6 gene were analyzed and the subjects were divided into 4 groups as wild-type or extensive metabolisers, heterozygotes for CYP2D6*10 and wild-type, homozygotes for CYP2D6*10, and subjects with one allele for poor metaboliser status. The groups in this order would be expected to have decreasing activity of the CYP2D6 enzyme. There was a tendency for greater reduction in LDL-cholesterol in groups with lower CYP2D6 activity, most obvious in male subjects and this was significant in the patients with familial hypercholesterolaemia comparing the first 3 groups. The fourth group had a low number of subjects, which may have biased that result. In the subjects without familial hypercholesterolaemia, the % change in LDL-cholesterol was similar in all genotype groups, but the % reduction in triglycerides was numerically higher in the wild-type group than in groups with CYP2D6*10 alleles and the group with poor metaboliser status showed a lower % reduction. These differences were not significant and may be influenced by the baseline levels of triglycerides, which were not corrected for in this analysis. / The daily calorie intake and percentage of different macronutrient intake was obtained by using seven days food recall records. Dietary intake of most nutrients with higher in male than in female patients and was higher in the patients compared to gender-matched population data. Higher intake of most nutrients was associated with higher baseline triglyceride levels, but not LDL-cholesterol levels in all patients, and in lower HDL-cholesterol levels in the patients without familial hypercholesterolaemia. Higher intake of total calories was associated with less percentage reduction in LDL-cholesterol with rosuvastatin in the patients without familial hypercholesterolaemia and a similar non-significant tendency was seen with higher intake of total fat, saturated fat and cholesterol. / The study described in this thesis examined the role of the CYP2D6*10 polymorphism on the lipid response to rosuvastatin in addition to a number of phenotypic factors such as diet, gender, measures of obesity and other medical conditions. / These findings suggest that the CYP2D6 genotype may have some influence on the lipid response to rosuvastatin, but it appears to interact with other factors including, gender, diet and the presence of familial hypercholesterolaemia. (Abstract shortened by UMI.) / Lui, Siu Hung. / "February 2007." / Adviser: Brian Tomlinson. / Source: Dissertation Abstracts International, Volume: 69-01, Section: B, page: 0248. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2007. / Includes bibliographical references (p. 165-190). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstracts in English and Chinese. / School code: 1307.
|
15 |
Prevalência de polimorfismos da enzima CYP2D6 em pacientes em terapia com psicotrópicos / Prevalence of CYP2D6 enzyme polymorphisms in patients on psychotropic therapyFERNANDES, Mauricio Avelar 28 April 2017 (has links)
Submitted by Rosivalda Pereira (mrs.pereira@ufma.br) on 2017-09-13T17:47:07Z
No. of bitstreams: 1
MauricioFernandes.pdf: 1547228 bytes, checksum: 87d9e63be597d8eaf8f7a783479e1294 (MD5) / Made available in DSpace on 2017-09-13T17:47:07Z (GMT). No. of bitstreams: 1
MauricioFernandes.pdf: 1547228 bytes, checksum: 87d9e63be597d8eaf8f7a783479e1294 (MD5)
Previous issue date: 2017-04-28 / Fundação de Amparo à Pesquisa e ao Desenvolvimento Científico e Tecnológico do Maranhão / INTRODUCTION: In Brazil, it is reported that a great part of the patients who arrive
for the primary care service have as main complaint: sadness (depression) and / or
anxiety, also with more complex disorders such as problems related to abuse of
alcohol and serious and persistent mental disorders, such as schizophrenia and
affective psychoses (bipolar mood disorder). In the pharmacogenetic studies of
antidepressants and antipsychotics, cytochrome P450 (CYPs) enzymes have been
shown to be one of the most significant targets in the interindividual changes in drug
response kinetic parameters. OBJECTIVE: To characterize the frequency of CYP2D6
polymorphisms (*4, *6 and *17) in users of psychotropic therapy, especially tricyclic
antidepressants and antipsychotics. METHODS: Cross - sectional, descriptive study
carried out in the city of São Luis – MA. RESULTS: From a total of 105 charts, a
sample of 43 patients was collected. The mean age was 40.98 (± 11.04) years, of
which 24 (55.81%) were male and 19 (44, 19%) of females. Regarding the
pharmacotherapy, all participants (100%) were on daily use of the antipsychotic
haloperidol, seventeen (39.53%) patients used risperidone and one (2.32%) patient
used amitriptyline (tricyclic antidepressant), all three drugs are substrates of the
enzyme CYP2D6. For the polymorphism of CYP2D6, we had a prevalence of 11
(25.48%) for allele 4, and all the patients presented with this polymorphism were
heterozygous, that means they had one polymorphic allele and one normal allele. For
allele 17, we had a prevalence of 4 (9.3%), also all patients being heterozygous for
this allele. Allele 6 did not appear in any patient in our study. We also had two
patients who presented the polymorphisms for alleles * 4 and * 17 at the same time.
CONCLUSION: This study was able to characterize the frequency of CYP2D6 (* 4, *
6 and 17 *) polymorphisms in users of psychotropic therapy, including tricyclic
antidepressants and antipsychotics, in addition to contributing to a higher dose /
response do medication, ensuring greater safety and efficacy in the use of
medicines, improving the quality of life of patients. / INTRODUÇÃO: No Brasil, tem-se o relato de que grande parte dos pacientes que
chegam para o atendimento na atenção primária apresentam, como principal queixa,
tristeza (depressão) e/ou ansiedade, aparecendo também transtornos mais
complexos como os problemas relacionados ao abuso de álcool, assim como os
transtornos mentais graves e persistentes, como a esquizofrenia e as psicoses
afetivas (transtorno bipolar do humor). Nos estudos farmacogenéticos de
antidepressivos e antipsicóticos, as enzimas do citrocromo P450 (CYPs) tem se
mostrado um dos alvos mais significativos nas alterações interindividuais dos
parâmetros cinéticos de resposta às drogas. OBJETIVO: caracterizar a frequência
de polimorfismos do CYP2D6 (*4, *6 e 17*) em usuários da terapêutica com
psicotrópicos, principalmente antidepressivos tricíclicos e antipsicóticos. MÉTODOS:
Estudo transversal, descritivo realizado no Município de São Luís (MA).
RESULTADO: De um total de 105 prontuários, coletou-se amostra de 43 pacientes,
a média de idade foi de 40,98 (±11,04) anos, sendo 24 (55,81%) do sexo masculino
e 19 (44,19%) do sexo feminino. Em relação à farmacoterapia, todos os
participantes (100%) estavam em consumo diário do antipsicótico haloperidol,
dezessete (39,53%) pacientes faziam uso de risperidona e um (2,32%) paciente
utilizava amitriptilina (antidepressivo tricíclico), todos os três medicamentos são
substratos da enzima CYP2D6. Para o polimorfismo da CYP2D6, tivemos para o
alelo 4 uma prevalência de 11 (25,48%), sendo que todos os pacientes que
apresentaram esse polimorfismo são heterozigotos, ou seja, apresentaram um alelo
polimórfico e outro normal. Para o alelo 17, tivemos uma prevalência de 4 (9,3%),
sendo também todos os pacientes heterozigotos para esse alelo. O alelo 6 não
apareceu em nenhum paciente do nosso estudo. Tivemos também dois pacientes
que apresentaram os polimorfismos para os alelos *4 e *17 ao mesmo tempo.
CONCLUSÃO: Este estudo pôde caracterizar a frequência de polimorfismos do
CYP2D6 (*4, *6 e 17*) em usuários da terapêutica com psicotrópicos, incluindo
antidepressivos tricíclicos e antipsicóticos, além de contribuir para uma maior
adequação da relação dose/resposta ao medicamento, garantindo maior segurança
e eficácia quanto ao uso de medicamentos, melhorando a qualidade de vida dos
pacientes.
|
Page generated in 0.0512 seconds